Dear Ms. Garcia-Davenport:


We acknowledge receipt of your submissions dated August 6, 1999, August 11 and August 28, 2000, received on August 9, 1999, August 11 and August 29, 2000, respectively.

Prior approval supplemental new drug application 005 provides for revisions to the labeling to include final data from the Arimidex oncogenicity program, and data from recently completed toxicology studies.

“Changes Being Effected” supplemental new drug application 009 provides for revisions to the ADVERSE REACTIONS section of the package insert. The changes that were proposed in supplement 009 were incorporated into the labeling for supplement 010 that was approved on September 5, 2002. Therefore, supplement 009 has been superseded by supplement 010 and will be acknowledged and retained.

We completed our review of supplement 005, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text with the minor editorial changes listed below:

1. In the WARNINGS section, the changes proposed in supplement 005 were superseded by the labeling for supplement 010 that was approved on September 5, 2002. The section should remain as worded in the labeling approved with supplement 010.

2. In the PRECAUTIONS section, Carcinogenesis subsection, the changes proposed in supplement 005 were superseded by the labeling for supplement 006 that was approved on September 1, 2000. The section should remain as worded in the labeling approved with supplement 006, with the following minor editorial change made to the first sentence at the next printing (change indicated by underline):

...
“A conventional carcinogenesis study in rats at doses of 1.0 to 25 mg/kg/day (about 10 to 243 times the daily maximum recommended human dose on a mg/m² basis) administered by oral gavage for up to 2 years revealed an increase in the incidence of hepatocellular adenoma and carcinoma and uterine stromal polyps in females and thyroid adenoma in males at the high dose.”

The final printed labeling (FPL) must be identical, and include the minor editorial revisions indicated, to the labeling approved with supplement 010 on September 5, 2002. These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplemental NDA 20-541/S-009.” Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amy Baird, Regulatory Project Manager, at (301) 594-5771.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Richard Pazdur
10/7/02 08:38:12 AM